RNAs May Help Identify Stage II Colon Cancer Patients Who May Benefit From Chemotherapy Following Surgery

The decision to treat patients with stage II colon cancer with adjuvant chemotherapy remains controversial. Therefore, there is an urgent need to identify reliable prognostic biomarkers that may be used to identify which patients would benefit from chemotherapy following surgery. In a ground-breaking studyopens in new tab/window investigators assess the biomarker potential of RNAs in stage II colon cancer. Their findings appear in The American Journal of Pathologyopens in new tab/window, published by Elsevier. 

Lead investigator Lasse Sommer Kristensen, PhD, Department of Biomedicine, Aarhus University, explains, “There are currently no reliable biomarkers for determining whether stage II colon cancer patients would benefit from adjuvant chemotherapy following surgery. Identification of new risk-stratification biomarkers is beneficial — it may spare many patients who are actually cured by the surgery from toxic side effects of chemotherapy while still selecting patients who would benefit from it.”

Using total RNA-sequencing, investigators profiled the landscape and differential expression of coding RNA, linear noncoding RNA, and circular RNA in stage II colon cancer patients with and without recurrence of the disease, as well as in stage III colon cancer patients. They also profiled adjacent normal tissues and liver metastases. The biomarker potential of differentially expressed RNAs in stage II colon cancer was subsequently evaluated. Patient data collected included age, sex, date of surgery, chemotherapy treatment, tumor location, and date of recurrence. Histopathologic data were collected through the Danish Pathology Registry (Patobank) and included staging status, histologic subtype, tumor differentiation, mismatch repair status, and mutational analysis, if performed.  

Sixty-two samples from 52 patients were included in the analysis: 18 patients with stage II colon cancer without recurrence, 10 patients with stage II colon cancer with recurrence, eight patients with stage III colon cancer with recurrence, 16 liver metastases, six adjacent normal colon tissues, and four adjacent normal liver tissues. 

The investigators found that RNAs with housekeeping functions, such as small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), and small Cajal body-specific RNAs (scaRNAs), were globally up-regulated in stage II patients who experienced recurrence compared to those who did not. Housekeeping RNAs are constitutively expressed and mostly involved in RNA splicing regulation and rRNA modification. 

This is the first study to comprehensively describe the landscape of mRNAs, linear noncoding RNAs, and circular RNAs in local and locally advanced colon cancer and unveiled numerous differentially expressed RNAs across various classes between recurrent and nonrecurrent colon cancer. The expression of these RNA classes is retained in liver metastases, suggesting that they may play important roles in the metastatic process. 

Dr Kristensen notes, “We were the first to profile many different types of RNA in stage II colon cancer patients with different outcomes and discovered novel individual biomarkers as well as entire classes of RNA that are commonly deregulated in patients with poor outcomes. Furthermore, many of these classes of RNAs showed great prognostic potential to assist treatment decisions in stage II colon cancer that should be validated in larger groups of patients.” 

Colon cancer is the third most common cancer and the second most deadly cancer worldwide, with more than one million new cases and more than half a million estimated cancer-related deaths per year. A considerable number of colon cancer patients with local or local advanced disease suffer from recurrence. Therefore, there is an urgent need for better prognostic biomarkers in this setting. Stage II colon cancer is defined by having penetrated the bowel wall, but without lymph node metastases or distant metastases at the time of diagnosis. 

Notes for editors 

The article is “The Transcriptional Landscape of Coding and Noncoding RNAs in Recurrent and Nonrecurrent Colon Cancer,” by Ulrik Korsgaard, Juan L. García-Rodríguez, Theresa Jakobsen, Ulvi Ahmadov, Kim-Gwendolyn Dietrich, Stine Mary Vissing, Thea Petersen Paasch, Jan Lindebjerg, Jørgen Kjems, Henrik Hager, and Lasse Sommer Kristensen (https://doi.org/10.1016/j.ajpath.2024.04.003opens in new tab/window). It appears online in The American Journal of Pathology, ahead of volume 194, issue 8 (August 2024), published by Elsevier. 

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(24)00163-9/fulltextopens in new tab/window. 

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected]opens in new tab/window to request a PDF of the article or more information. To reach the study’s authors contact Lasse Sommer Kristensen, PhD, at [email protected]opens in new tab/window.  

This study was supported by Lundbeck Foundation grant R307-2018-3433; Riisfort Fonden; Magda Sofie Og Aase Lütz’s Mindelegat Fond; Novo Nordisk Foundation ODIN program grant NNF20SA0061466; Danish Cancer Society grants R304-A17698 and R269-A15768; Region of Southern Denmark grant 20/15099; Research Council at Lillebaelt Hospital grant R27-A896; and Købmand i Odense Johann og Hanne Weimann Født Seedorffs Legat. 

About The American Journal of Pathology 

The American Journal of Pathologyopens in new tab/window, official journal of the American Society for Investigative Pathologyopens in new tab/window, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. https://ajp.amjpathol.orgopens in new tab/window 

About Elsevier

As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy.

Together with the Elsevier Foundationopens in new tab/window, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELXopens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.